Critical care trial design and interpretation: A primer

Critical Care Medicine

Volumn 38, Issue 9, 2010, Pages 1882-1889

  Sevransky, Jonathan E ^a   Checkley, William ^a,b   Martin, Greg S ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adult; clinical trial; critical care; outcomes

Indexed keywords

CLINICAL PRACTICE; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; EXTERNAL VALIDITY; HUMAN; INTENSIVE CARE; INTERNAL VALIDITY; OBSERVER BIAS; PATIENT SELECTION; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SAMPLE SIZE; STUDY DESIGN; THERAPY EFFECT; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); METHODOLOGY;

CLINICAL TRIALS AS TOPIC; CRITICAL CARE; HUMANS; RESEARCH DESIGN;

EID: 77956229376     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181eae226     Document Type: Review

References (73)

1. Safar P, Dekornfeld TJ, Pearson JW, et al: The intensive care unit. A three year experience at Baltimore city hospitals. Anaesthesia 1961; 16:275-284.
2. Vincent JL, Fink MP, Marini JJ, et al: Intensive care and emergency medicine: Progress over the past 25 years. Chest 2006; 129: 1061-1067.
3. Reade MC, Angus DC: The clinical research enterprise in critical care: What's right, what's wrong, and what's ahead? Crit Care Med 2009; 37:S1-S9.
4. Phua J, Badia JR, Adhikari NK, et al: Has mortality from acute respiratory distress syndrome decreased over time? A systematic review. Am J Respir Crit Care Med 2009; 179: 220-227.
5. Szklo M, Nieto FJ: Epidemiology. Second Edition. Sudbury, MA, Jones and Bartlett, 2007.
6. Chaix C, Durand-Zaleski I, Alberti C, et al: Control of endemic methicillin-resistant Staphylococcus aureus: A cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745-1751.
7. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892.
8. Herridge MS, Cheung AM, Tansey CM, et al: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003; 348:683-693.
9. Piantadosi S: Clinical Trials: A Methodologic Perspective. Second Edition. Hoboken, NJ, John Wiley and Sons, 2005.
10. Meinert CL: Clinical Trials: Design, Conduct, and Analysis. New York, NY, Oxford University Press, 1986.
11. Derdak S, Mehta S, Stewart TE, et al: Highfrequency oscillatory ventilation for acute respiratory distress syndrome in adults: A randomized, controlled trial. Am J Respir Crit Care Med 2002; 166:801-808.
12. National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al: Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224.
13. National Heart, Lung, Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575.
14. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139.
15. Sackett DL: Equipoise, a term whose time (if it ever came) has surely gone. CMAJ 2000; 163:835-836.
16. Shapiro SH, Glass KC: Why Sackett's analysis of randomized controlled trials fails, but needn't. CMAJ 2000; 163:834-835.
17. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886.
18. Connors AF Jr, Speroff T, Dawson NV, et al: The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996; 276:889-897.
19. Guyatt G: A randomized control trial of right-heart catheterization in critically ill patients. Ontario Intensive Care Study Group. J Intensive Care Med 1991; 6:91-95.
20. Sandham JD, Hull RD, Brant RF, et al: A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5-14.
21. Richard C, Warszawski J, Anguel N, et al: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: A randomized controlled trial. JAMA 2003; 290: 2713-2720.
22. LeLorier J, Grégoire G, Benhaddad A, et al: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997; 337:536-542.
23. Annane D, Sébille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
24. Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
25. Parshuram CS, Kavanagh BP: Positive clinical trials: Understand the control group before implementing the result. Am J Respir Crit Care Med 2004; 170:223-226.
26. Cowles MK: Bayesian estimation of the proportion of treatment effect captured by a surrogate marker. Stat Med 2002; 21: 811-834.
27. Kalish LA, McIntosh K, Read JS, et al: Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level, and clinical class as time-fixed and time-varying markers of disease progression in HIV-1-infected children. J Infect Dis 1999; 180: 1514-1520.
28. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27:639-660.
29. Bakker J, Grover R, McLuckie A, et al: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebocontrolled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12.
30. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
31. Taccone P, Pesenti A, Latini R, et al: Prone positioning in patients with moderate and severe acute respiratory distress syndrome: A randomized controlled trial. JAMA 2009; 302: 1977-1984.
32. Taylor RW, Zimmerman JL, Dellinger RP, et al: Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 2004; 291:1603-1609.
33. Abroug F, Ouanes-Besbes L, Elatrous S, et al: The effect of prone positioning in acute respiratory distress syndrome or acute lung injury: A meta-analysis. Areas of uncertainty and recommendations for research. Intensive Care Med 2008; 34:1002-1011.
34. Ware LB, Koyama T, Billheimer DD, et al: Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137:288-296.
35. Tomlinson G, Detsky AS: Composite end points in randomized trials: There is no free lunch. JAMA 2010; 303:267-268.
36. Guyatt GH, Sinclair J, Cook DJ, et al: Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. JAMA 1999; 281:1836-1843.
37. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308.
38. Checkley W, Brower RG, Muñ oz A: Inference for mutually exclusive competing events through a mixture of generalized gamma distributions. Epidemiology 2010; 21:557-565.
39. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports or parallel-group randomised trials. Lancet 2001; 357:1191-1194.
40. von Elm E, Altman DG, Egger M, et al: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
41. Wittes J: Sample size calculations for randomized controlled trials. Epidemiol Rev 2002; 24:39-53.
42. Dupont WD, Plummer WD Jr: Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19:589-601.
43. Day SJ, Graham DF: Sample size estimation for comparing two or more treatment groups in clinical trials. Stat Med 1991; 10:33-43.
44. Whitehead J: The Design and Analysis of Sequential Clinical Trials. Second Edition. Chichester, UK, John Wiley and Sons, 1997.
45. Pocock S, White I: Trials stopped early: Too good to be true? Lancet 1999; 353:943-944.
46. Montori VM, Devereaux PJ, Adhikari NK, et al: Randomized trials stopped early for benefit: A systematic review. JAMA 2005; 294: 2203-2209.
47. Pocock SJ, Hughes MD: Practical problems in interim analyses, with particular regard to estimation. Control Clin Trials 1989; 10: 209S-221S.
48. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
49. Russell JA, Walley KR, Singer J, et al: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
50. Spragg RG, Bernard GR, Checkley W, et al: Beyond mortality: Future clinical research in acute lung injury. An NHLBI workshop report. Am J Respir Crit Care Med 2010; 181: 1121-1127.
51. Grimes DA, Schulz KF: Bias and causal associations in observational research. Lancet 2002; 359:248-252.
52. Bernard GR, Artigas A, Brigham KL, et al: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
53. Rubenfeld GD, Caldwell E, Granton J, et al: Interobserver variability in applying a radiographic definition for ARDS. Chest 1999; 116:1347-1353.
54. Guyatt GH (Ed): Users' Guides to the Medical Literature. Columbus, OH, McGraw-Hill, 2008.
55. Dhainaut JF, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26: 1963-1971.
56. Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-1124.
57. Knaus WA, Harrell FE Jr, LaBrecque JF, et al: Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24:46-56.
58. Natanson C, Esposito CJ, Banks SM: The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998; 26:1927-1931.
59. Cook DI, Gebski VJ, Keech AC: Subgroup analysis in clinical trials. Med J Aust 2004; 180:289-291.
60. Cook D, Crowther M: Targeting anemia with erythropoietin during critical illness. N Engl J Med 2007; 357:1037-1039.
61. Finfer S, Bellomo R, Boyce N, et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247-2256.
62. Pocock SJ, Ware JH: Translating statistical findings into plain English. Lancet 2009; 373:1926-1928.
63. Bellomo R, Warrillow SJ, Reade MC: Why we should be wary of single-center trials. Crit Care Med 2009; 37:3114-3119.
64. Sweeney DA, Danner RL, Eichacker PQ, et al: Once is not enough: Clinical trials in sepsis. Intensive Care Med 2008; 34:1955-1960.
65. Levy MM: Facilitating knowledge transfer with single-center trials. Crit Care Med 2009; 37:3120-3123.
66. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657-1666.
67. Cook RJ, Bergeron PJ, Boher JM, et al: Twostage design of clinical trials involving recurrent events. Stat Med 2009; 28:2617-2638.
68. Elkind MS, Sacco RL, MacArthur RB, et al: The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): An adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke 2008; 3:210-218.
69. Haley EC Jr, Thompson JL, Grotta JC, et al: Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial. Stroke 2010; 41:707-711.
70. De Backer D, Biston P, Devriendt J, et al: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789.
71. Pene F, Courtine E, Cariou A, et al: Toward theragnostics. Crit Care Med 2009; 37: S50-S58.
72. Attia J, Ioannidis JP, Thakkinstian A, et al: How to use an article about genetic association: C: What are the results and will they help me in caring for my patients? JAMA 2009; 301:304-308.
73. Panacek EA, Marshall JC, Albertson TE, et al: Efficacy and safety of the monoclonal antitumor necrosis factor antibody F(ab)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-2182